We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

2 hedge funds and large institutions have $201K invested in VanEck Vectors Generic Drugs ETF in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 4 → 2 (-2)

73% less capital invested

Capital invested by funds: $732K → $201K (-$531K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$271K
2
Citadel Advisors
Citadel Advisors
Florida
-$259K
3
APA
American Portfolios Advisors
New York
-$2.01K
Name Holding Trade Value Shares
Change 		Change in
Stake
APA
1
American Portfolios Advisors
New York
$177K -$2.01K -80 -1%
Bank of America
2
Bank of America
North Carolina
$24K – – –
Jane Street
3
Jane Street
New York
– -$271K -11,145 Closed
Citadel Advisors
4
Citadel Advisors
Florida
– -$259K -10,661 Closed

GNRX Hedge Fund Activity: Q1 2018 in Review

2 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q1 2018, worth a combined $201K — down 73% from $732K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of GNRX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Jane Street, exiting entirely with an estimated $271K sold.

  • 2 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q1 2018, down from 4 in Q4 2017.
  • Funds reported $201K of VanEck Vectors Generic Drugs ETF stock for Q1 2018, down 73% quarter-over-quarter.
  • 0 funds opened new VanEck Vectors Generic Drugs ETF positions in Q1 2018 and 2 closed out, a net change of -2 holders.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q1 2018 was Jane Street, an estimated $271K sold.

Based on aggregated 13F filings for Q1 2018.